Waldenström Macroglobulinemia and Chronic Myelomonocytic Leukemia: Case Report and Literature Review

Yueyue Pan,1 Yan Wang,2 Qiong Wang1 1The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, People’s Republic of China; 2The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, People’s Republic of ChinaCorrespondence: Qiong Wang, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, People’s Republic of China, Email [email protected] Yan Wang, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, People’s Republic of China, Email [email protected]: As hematological tumor patients are surviving long-term, the long-term toxicities of therapeutic regimens have become increasingly evident. The coexistence of two hematological tumors in the same patient is extremely rare and typically shows an aggressive clinical course and unsatisfactory prognosis. In the present case, we describe the case of a 64-year-old man who was admitted to the hospital because of fatigue. Biochemical showed an elevated monoclonal immunoglobulin M (IgM) at 37g/L. Next Generation Sequencing (NGS) analysis revealed MYD88L265p mutation, CXCR4 wild type. In August 2020, he was diagnosed with Waldenström macroglobulinemia (WM) and underwent six cycles of chemotherapy with bendamustine, zanubrutinib, and rituximab. However, he was admitted to the hospital in December 2022 following six-month history of Leukocytosis. Bone marrow (BM) flow cytometry (FCM) showed increased MO1 monocytes. Molecular studies were positive for TET2 mutations. He was finally diagnosed with WM and chronic myelomonocytic leukemia (CMML). Then he accepted hematopoietic stem cell transplantation (HSCT). Unfortunately, after 6 months, the patient died as a consequence of severe pulmonary infection.Keywords: Waldenström macroglobulinemia, chronic myelomonocytic leukemia, lymphoproliferative disorder, hematopoietic stem cell disorder, hematopoietic stem cell transplantation

Publication Details

Journal
Dove Medical Press (Taylor and Francis Group)
Published
2025-04-03
Primary Topic
Sports Performance and Training
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Waldenström Macroglobulinemia and Chronic Myelomonocytic Leukemia: Case Report and Literature Review

Dove Medical Press (Taylor and Francis Group)
Sports Performance and Training
article

Waldenström Macroglobulinemia and Chronic Myelomonocytic Leukemia: Case Report and Literature Review

article en

Abstract

Yueyue Pan,1 Yan Wang,2 Qiong Wang1 1The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, People’s Republic of China; 2The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, People’s Republic of ChinaCorrespondence: Qiong Wang, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, People’s Republic of China, Email [email protected] Yan Wang, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, People’s Republic of China, Email [email protected]: As hematological tumor patients are surviving long-term, the long-term toxicities of therapeutic regimens have become increasingly evident. The coexistence of two hematological tumors in the same patient is extremely rare and typically shows an aggressive clinical course and unsatisfactory prognosis. In the present case, we describe the case of a 64-year-old man who was admitted to the hospital because of fatigue. Biochemical showed an elevated monoclonal immunoglobulin M (IgM) at 37g/L. Next Generation Sequencing (NGS) analysis revealed MYD88L265p mutation, CXCR4 wild type. In August 2020, he was diagnosed with Waldenström macroglobulinemia (WM) and underwent six cycles of chemotherapy with bendamustine, zanubrutinib, and rituximab. However, he was admitted to the hospital in December 2022 following six-month history of Leukocytosis. Bone marrow (BM) flow cytometry (FCM) showed increased MO1 monocytes. Molecular studies were positive for TET2 mutations. He was finally diagnosed with WM and chronic myelomonocytic leukemia (CMML). Then he accepted hematopoietic stem cell transplantation (HSCT). Unfortunately, after 6 months, the patient died as a consequence of severe pulmonary infection.Keywords: Waldenström macroglobulinemia, chronic myelomonocytic leukemia, lymphoproliferative disorder, hematopoietic stem cell disorder, hematopoietic stem cell transplantation

Dove Medical Press (Taylor and Francis Group)
Good health and well-being
Openalex Percentile: Top 42%
Sports Performance and Training
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Waldenström Macroglobulinemia and Chronic Myelomonocytic Leukemia: Case Report and Literature Review · Dove Medical Press (Taylor and Francis Group) (2025) | TGRS Research Map | TGRS